Placenta study aims to unlock drug safety in pregnancy
NCT ID NCT04400084
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study uses placentas donated after childbirth to measure how drugs pass from mother to fetus. Researchers will perfuse the placenta in a lab to calculate drug transfer rates. The goal is to fill a gap in knowledge about medication safety during pregnancy, since pregnant women are often excluded from drug trials. Up to 2,000 women with normal pregnancies will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand which drugs are safe during pregnancy and how they affect the fetus.
- What could go wrong
- This is an ex vivo lab study using placentas after birth, not a treatment trial. Results may not fully predict real-life drug effects in pregnant women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NORMAL PREGNANCY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIC Port-Royal-Cochin
RECRUITINGParis, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.